Gain Therapeutics regains Nasdaq compliance with $50M market value requirement

Gain Therapeutics, Inc.

Received Nasdaq letter on Oct 21, 2024 confirming regained compliance with MVLS Requirement.
Previously non-compliant as of July 11, 2024; had until Jan 7, 2025 to cure.
Compliance now achieved; matter closed with no further action needed.
Regained compliance ensures continued listing on The Nasdaq Global Market.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.